Asymmetric hydrogenation of a 4,4-diaryl-3-butenoate; a novel approach to sertraline.
The asymmetric hydrogenation of a selectively crystallised (E)-4,4-diaryl-3-butenoate with a rhodium-PhanePhos catalyst is described, providing an intermediate to the antidepressant sertraline.
Boulton
Lee T
LT
Dowpharma, Chirotech Technology Limited, Dow Chemical Company, Cambridge Science Park, Unit 321, Milton Road, Cambridge, UK CB4 0WG. lboulton@dow.com
Lennon
Ian C
IC
McCague
Raymond
R
D000928:Antidepressive Agents / Q000138:chemical synthesis* / Q000737:chemistry; D002087:Butyrates / Q000737:chemistry*; D002384:Catalysis; D006865:Hydrogenation; D015394:Molecular Structure; D012238:Rhodium / Q000737:chemistry; D020280:Sertraline / Q000138:chemical synthesis* / Q000737:chemistry
D000928:Antidepressive Agents; D002087:Butyrates; D012238:Rhodium; D020280:Sertraline